Table 2.
Characteristics of all patients.
| Characteristics | Value |
|---|---|
| N | |
| EMVI +, n (%) | 78 (42.4) |
| EMVI −, n (%) | 106 (57.6) |
| Age (years), M ± SD, range (years)/ Me (Q1; Q3) | 65.55 ± 10.83, 36–87/65.69 (58.97; 72.32) |
| Sex (female), n (%) | 73 (39.9) |
| Tumor, n (%) | |
| T2-T3 | 146 (80.7) |
| T4 | 35 (19.3) |
| Lymph nodes, n (%) | |
| N0 | 68 (41.2) |
| N1 | 63 (38.2) |
| N2 | 34 (26.0) |
| Stage, n (%) | |
| II-III A | 84 (47.2) |
| III B | 65 (36.5) |
| III C | 29 (16.3) |
| ALC (109/L), M ± SD | 1.77 (1.38; 2.24) |
| AMC (109/L), Me (Q1; Q3) | 0.60 (0.50; 0.76) |
| ANC (109/L), Me (Q1; Q3) | 4.77 (3.77; 5.99) |
| Platelets (109/L), Me (Q1; Q3) | 274.50 (230.75; 337.25) |
| LMR, Me (Q1; Q3) | 2.87 (2.25; 3.81) |
| NLR, Me (Q1; Q3) | 2.62 (2.09; 3.42) |
| PLR, Me (Q1; Q3) | 153.11 (117.98; 204.10) |
| CEA (ng/mL), Me (Q1; Q3) | 3.88 (2.33; 9.06) |
| CA19-9 (U/mL), Me (Q1; Q3) | 10.04 (4.64; 17.73) |
EMVI, extramural vascular invasion; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-monocyte ratio; PLR, platelet-to-lymphocyte ratio; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; M, mean; SD, standard deviation; Q, quartile; Me, median.